Combination targeted therapy in advanced renal cell carcinoma.

  title={Combination targeted therapy in advanced renal cell carcinoma.},
  author={Jeffrey A. Sosman and Igor J. Puzanov},
  volume={115 10 Suppl},
Several novel therapies have been approved recently in advanced renal cell carcinoma (RCC). These agents inhibit pathways downstream of loss of the von Hippel-Lindau gene VHL. They target the vascular endothelial growth factor (VEGF) ligand, VEGF receptor (VEGFR), mammalian target of rapamycin (mTOR), and other potentially important pathways. Even with improvements in survival, disease progresses in all patients. There is a critical need to increase complete responses (now rare). One such… CONTINUE READING